Petretta M, Morgano G, Arrichiello P, Breglio R, Lanzillo T, Mazza F, Bonaduce D
Istituto di Medicina Interna, II Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli.
G Ital Cardiol. 1990 Jun;20(6):518-25.
The safety and efficacy of a new dihydropyridine calcium antagonist, nisoldipine, were studied in comparison with propranolol, in patients with stable angina. Following 2 weeks of wash-out of the current therapy and 1 week of placebo, 26 patients underwent two cycloergometer tests, before and 2 hours after placebo administration. Subsequently, 10 mg of nisoldipine twice daily or 40 mg of propranolol three times daily were administered over a 4 week period, in a randomized single-blind fashion. Cycloergometer tests were performed after 2 and 4 weeks, before and two hours after drug administration. Two patients, one out of the nisoldipine group and one out of the propranolol, were considered drop outs. Statistical analysis of the results was performed using two-way variance analysis. With both drugs, time to 1 mm exercise induced ST-segment depression (p less than 0.01), time to angina (p less than 0.01), and exercise tolerance (p less than 0.01) improved furthermore, ST-segment and heart rate recovery time decreased (p less than 0.01). Rate-pressure product values at ischemic threshold and at peak exercise remained unchanged with nisoldipine, while significant reductions were observed with propranolol (p less than 0.01). Maximum ST-segment depression was reduced (p less than 0.01) with both drugs and a further improvement was observed two hours after drug administration (p less than 0.05). At submaximum work-load, rate pressure product values and ST-segment depression were improved with both drugs (p less than 0.01); this improvement was more evident two hours after drug administration. No significant side effects were observed with either drug.(ABSTRACT TRUNCATED AT 250 WORDS)
在稳定性心绞痛患者中，将一种新型二氢吡啶类钙拮抗剂尼索地平与普萘洛尔进行比较，研究了其安全性和有效性。在停用当前治疗2周并服用1周安慰剂后，26例患者在服用安慰剂前和服用后2小时进行了两次运动功率计测试。随后，以随机单盲方式在4周内每日两次给予10 mg尼索地平或每日三次给予40 mg普萘洛尔。在给药2周和4周后，给药前和给药后2小时进行运动功率计测试。两名患者，一名来自尼索地平组，一名来自普萘洛尔组，被视为退出研究。使用双向方差分析对结果进行统计分析。使用两种药物时，运动诱发ST段压低1 mm的时间（p<0.01）、心绞痛发作时间（p<0.01）和运动耐量（p<0.01）进一步改善，ST段和心率恢复时间缩短（p<0.01）。尼索地平治疗后，缺血阈值和运动峰值时的速率-压力乘积值保持不变，而普萘洛尔治疗后显著降低（p<0.01）。两种药物均使最大ST段压低程度降低（p<0.01），给药后2小时进一步改善（p<0.05）。在次最大工作量时，两种药物均使速率-压力乘积值和ST段压低程度改善（p<0.01）；给药后2小时这种改善更明显。两种药物均未观察到明显的副作用。（摘要截断于250字）
